Solugen
-27%
est. 2Y upside i
Decarbonizing the chemicals industry.
Rank
#3435
Sector
Biomanufacturing
Est. Liquidity
~3Y
Data Quality
Data: LowSolugen's secondary valuation of $625M and heavy preference stack ($870M) imply common equity is deeply underwater.
Last updated: July 3, 2026
IPO window opens and defense contracts scale revenue faster; exit multiple holds at 7x on $156M revenue for a $1.09B exit (74.7% before 20% dilution).
Growth continues but multiple converges to public comp median of 5x, yielding $780M exit (24.8% before 20% dilution); equity barely positive.
Revenue underperforms, multiple compresses to 3x, exit value $468M below $870M preferred stack; common stock worthless.
Preference Stack Risk
severeFunding Intensity
13920%Total funding of $870M exceeds secondary valuation of $625M by 39%, implying preferred holders take all proceeds in a downside exit.
Dilution Risk
highWith only $2B round mark in 2022 and significant cash burn, another large equity raise within 24 months is likely, diluting common by ~20%.
Secondary Liquidity
limitedSecondary market exists (implied $625M valuation) but with limited volume and wide bid-ask spreads.
Questions to Ask at the Interview
Strategic questions based on Solugen's data — designed to show you've done your homework.
- 1
“How does Solugen's unit economics compare to incumbent petrochemicals at scale?”
- 2
“What is the roadmap to profitability given the high capital intensity?”
- 3
“How does the DOE loan affect dilution and your equity's path to liquidity?”
Community
Valuation Sentiment
Our model estimates -27% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.